Fusion Antibodies plc (LON:FAB – Get Free Report) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as GBX 3 ($0.04) and last traded at GBX 3.10 ($0.04), with a volume of 139327 shares. The stock had previously closed at GBX 3.17 ($0.04).
Fusion Antibodies Price Performance
The company has a market capitalization of £2.96 million, a P/E ratio of -34.44 and a beta of 0.46. The business’s 50-day moving average is GBX 3.46 and its two-hundred day moving average is GBX 3.98. The company has a quick ratio of 2.36, a current ratio of 3.26 and a debt-to-equity ratio of 3.23.
Fusion Antibodies Company Profile
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.
Recommended Stories
- Five stocks we like better than Fusion Antibodies
- 3 Stocks to Consider Buying in October
- The Meaning Behind Short Interest: Beyond the Short Squeeze Hype
- Airline Stocks – Top Airline Stocks to Buy Now
- Savvy Investors’ Rate Cut Portfolio: Bonds, Small Caps, Energy
- How Can Investors Benefit From After-Hours Trading
- Generac Holdings Stock: Mixed Signals Leave Investors Uncertain
Receive News & Ratings for Fusion Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fusion Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.
